The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
COVID-19 Updates: COVID-19 Resources » Vaccine Update » Updated Visitor Policy » What We're Doing to Keep You Safe »


Philip Grant
Positive care doctor, Infectious disease doctor
Professional Education
- Residency: University of Washington Medical Center Dept of Medicine (2003) WA
- Internship: University of Washington Medical Center Dept of Medicine (2001) WA
- Medical Education: University of California at San Francisco School of Medicine (2000) CA
- Fellowship, Stanford University Infectious Dseases (2010)
- Board Certification: American Board of Internal Medicine, Infectious Disease (2008)
Publications
-
Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores
Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., Nadler, J., … Zolopa, A. (2008). Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4050–56. -
Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
Grant, P., & Zolopa, A. (2008). Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Journal of HIV Therapy, 13(2), 36–39. -
Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor
Grant, P., Taylor, J., Cain, P., Short, W., Gallant, J., Farthing, C., … Zolopa, A. (2009). Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. CLINICAL INFECTIOUS DISEASES, 48(5), 680–82. -
Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.
Grant, P., & Zolopa, A. (2009). Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Current HIV/AIDS Reports, 6(2), 63–67.
-
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life
Grant, P. M., Palmer, S., Bendavid, E., Talbot, A., Slamowitz, D. C., Cain, P., … Zolopa, A. R. (2009). Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. JOURNAL OF CLINICAL VIROLOGY, 46(4), 305–8.
-
The use of resistance testing in the management of HIV-1-infected patients
Grant, P. M., & Zolopa, A. R. (2009). The use of resistance testing in the management of HIV-1-infected patients. CURRENT OPINION IN HIV AND AIDS, 4(6), 474–80.
-
International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase
Grant, P. M., Taylor, J., Nevins, A. B., Calvez, V., Marcelin, A.-G., Wirden, M., & Zolopa, A. R. (2010). International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(4), 1520–25.
-
Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors
Talbot, A., Grant, P., Taylor, J., Baril, J.-G., Liu, T. F., Charest, H., … Zolopa, A. (2010). Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2473–2479.
-
Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection
Grant, P. M., Komarow, L., Andersen, J., Sereti, I., Pahwa, S., Lederman, M. M., … Zolopa, A. (2010). Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLOS ONE, 5(7).
-
Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance
Grant, P. M., & Zolopa, A. R. (2010). Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 11(8), 901–10.
-
Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis
Grant, P. M., Aberg, J. A., & Zolopa, A. R. (2010). Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis. CLINICAL INFECTIOUS DISEASES, 51(8), 984–985.
-
Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis
Bendavid, E., Grant, P., Talbot, A., Owens, D. K., & Zolopa, A. (2011). Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS, 25(2), 211–20.
-
When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!
Grant, P. M., & Zolopa, A. R. (2012). When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Current HIV/AIDS Reports, 9(3), 251–58.
-
Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164
Grant, P. M., Komarow, L., Lederman, M. M., Pahwa, S., Zolopa, A. R., Andersen, J., … Sereti, I. (2012). Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164. JOURNAL OF INFECTIOUS DISEASES, 206(11), 1715–23.
-
Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164
Sax, P. E., Sloan, C. E., Schackman, B. R., Grant, P. M., Rong, J., Zolopa, A. R., … Freedberg, K. A. (2010). Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. HIV CLINICAL TRIALS, 11(5), 248–259.
-
Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia
Sax, P. E., Komarow, L., Finkelman, M. A., Grant, P. M., Andersen, J., Scully, E., … Zolopa, A. R. (2011). Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia. CLINICAL INFECTIOUS DISEASES, 53(2), 197–202.
-
Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation.
Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., Huang, J., … Brown, T. T. (2013). Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. Clinical Infectious Diseases , 57(10), 1483–88.
-
TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY
Talbot, A., Uwihoreye, C., Kamen, C., Grant, P., McGlynn, L., Mugabe, I., … Zolopa, A. (2013). TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY. AIDS EDUCATION AND PREVENTION, 25(6), 468–79.
-
Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202
Grant, P. M., Tierney, C., Budhathoki, C., Daar, E. S., Sax, P. E., Collier, A. C., … Katzenstein, D. (2013). Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202. HIV CLINICAL TRIALS, 14(6), 284–91.
-
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Medicine, 12, 46-?
-
Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations
Richardson, E. T., Grant, P. M., & Zolopa, A. R. (2014). Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations. ANTIVIRAL RESEARCH, 103, 88–93.
-
Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults.
Liang, E. C., Sceats, L., Bayless, N. L., Strauss-Albee, D. M., Kubo, J., Grant, P. M., … Blish, C. A. (2014). Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults. Journal of Virology, 88(15), 8629–39.
-
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Medicine, 12, 46-?
-
Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164
Grant, P. M., Komarow, L., Sanchez, A., Sattler, F. R., Asmuth, D. M., Pollard, R. B., & Zolopal, A. R. (2014). Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164. HIV CLINICAL TRIALS, 15(4), 133–39.
-
Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga.
Nelson, J., Waggoner, J. J., Sahoo, M. K., Grant, P. M., & Pinsky, B. A. (2014). Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga. Journal of Clinical Microbiology, 52(9), 3459–61.
-
Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen
Lee, A. J., Bosch, R. J., Evans, S. R., Wu, K., Harrison, T., Grant, P., & Clifford, D. B. (2015). Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen. JOURNAL OF NEUROVIROLOGY, 21(2), 210–18.
-
Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults
Grant, P. M., Kitch, D., McComsey, G. A., Tierney, C., Ha, B., & Brown, T. T. (2015). Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV CLINICAL TRIALS, 16(2), 66–71.
-
Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma
Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., & Pinsky, B. A. (2015). Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93(2), 238–40.
-
Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma.
Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., & Pinsky, B. A. (2015). Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma. American Journal of Tropical Medicine and Hygiene, 93(2), 238–40.
-
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
Collins, S. E., Grant, P. M., & Shafer, R. W. (2016). Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. DRUGS, 76(1), 75–98.
-
Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients
Grant, P. M., Sheikh, V., DerSimonian, R., Rupert, A., Roby, G., Pau, A., … Sereti, I. (2015). Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 31(7), 739–44.
-
Tenofovir and bone health
Grant, P. M., & Cotter, A. G. (2016). Tenofovir and bone health. CURRENT OPINION IN HIV AND AIDS, 11(3), 326–32.
-
When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now!
Grant, P. M., & Zolopa, A. R. (2012). When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now! CURRENT HIV/AIDS REPORTS, 9(3), 251–258.
-
Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals
Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Koletar, S. L., Erlandson, K. M., … Brown, T. T. (2016). Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals. JOURNAL OF INFECTIOUS DISEASES, 214(4), 607–11.
-
A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.
Collins, S. E., Grant, P. M., Uwinkindi, F., Talbot, A., Seruyange, E., Slamowitz, D., … Nsanzimana, S. (2016). A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans. Open Forum Infectious Diseases, 3(3), ofw141-?
-
Long-term body composition changes in antiretroviral-treated HIV-infected individuals
Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Bartali, B., Koletar, S. L., … Brown, T. T. (2016). Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS, 30(18), 2805–13.
-
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Paredes, R., Tzou, P. L., van Zyl, G., Barrow, G., Camacho, R., Carmona, S., … Shafer, R. W. (2017). Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PloS One, 12(7), e0181357.
-
High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study
Gupta, N., Kabahizi, J., Muvunyi, C., Mbituyumuremyi, A., Van Nuil, J. I., & Grant, P. M. (2017). High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study. HEPATOLOGY, 66, 615A.
-
Effect of Testosterone Use on Bone Mineral Density in HIV-infected Men.
Grant, P. M., Li, X., Jacobson, L., Palella, F. J., Kingsley, L., Margolick, J. B., … Brown, T. (2018). Effect of Testosterone Use on Bone Mineral Density in HIV-infected Men. AIDS Research and Human Retroviruses.
-
Safety and Efficacy of Ledipasvir/Sofosbuvir without on-Treatment Laboratory Monitoring in HCV-Infected Rwandans: The Shared 2 Study
Grant, P., Kabahizi, J., Mbituyumuremyi, A., Van Nuil, J. I., Mukabatsinda, C., Damascene, M. J., … Gupta, N. (2018). Safety and Efficacy of Ledipasvir/Sofosbuvir without on-Treatment Laboratory Monitoring in HCV-Infected Rwandans: The Shared 2 Study. HEPATOLOGY, 68, 36A.
-
A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus.
Mellor-Crummey, L. E., Lake, J. E., Wilhalme, H., Tseng, C.-H., Grant, P. M., Erlandson, K. M., … Brown, T. T. (2018). A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. Journal of Clinical Gastroenterology and Hepatology, 2(3).
-
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Gupta, N., Mbituyumuremyi, A., Kabahizi, J., Ntaganda, F., Muvunyi, C. M., Shumbusho, F., … Grant, P. M. (2018). Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. The Lancet. Gastroenterology & Hepatology.
-
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.
Collins, S. E., Grant, P. M., & Shafer, R. W. (2016). Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Drugs, 76(1), 75–98.
-
Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men
Grant, P. M., Li, X., Jacobson, L. P., Palella, F. J., Kingsley, L. A., Margolick, J. B., … Brown, T. T. (2019). Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men. AIDS RESEARCH AND HUMAN RETROVIRUSES, 35(1), 75–80.
-
A systematic review of the genetic mechanisms of dolutegravir resistance.
Rhee, S.-Y. Y., Grant, P. M., Tzou, P. L., Barrow, G., Harrigan, P. R., Ioannidis, J. P., & Shafer, R. W. (2019). A systematic review of the genetic mechanisms of dolutegravir resistance. The Journal of Antimicrobial Chemotherapy.
-
Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda
Grant, P., Shumbusho, F., Van Nuil, J. I., Kateera, F., Mukherjee, J., Kabahizi, J., … Gupta, N. (2020). Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. HEPATOLOGY COMMUNICATIONS.
-
Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda.
Grant, P., Shumbusho, F., Van Nuil, J. I., Kateera, F., Mukherjee, J., Kabahizi, J., … Gupta, N. (2020). Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. Hepatology Communications, 4(4), 569–76.
-
Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection.
Ramadoss, N. S., Zhao, N. Q., Richardson, B. A., Grant, P. M., Kim, P. S., & Blish, C. A. (2020). Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection. AIDS (London, England).
-
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Goldman, J. D., Lye, D. C., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., … Subramanian, A. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England Journal of Medicine.
-
Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells.
Zhao, N. Q., Ferreira, A.-M., Grant, P. M., Holmes, S., & Blish, C. A. (2020). Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells. Frontiers in Immunology, 11, 829.
-
A single-cell atlas of the peripheral immune response in patients with severe COVID-19.
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martinez-Colon, G. J., McKechnie, J. L., … Blish, C. A. (2020). A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nature Medicine.
-
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.
Wilson, J. G., Simpson, L. J., Ferreira, A.-M., Rustagi, A., Roque, J. A., Asuni, A., … Rogers, A. J. (2020). Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight.
-
Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease.
Igbinosa, I., Miller, S., Bianco, K., Nelson, J., Kappagoda, S., Blackburn, B. G., … Aziz, N. (2020). Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease. American Journal of Obstetrics and Gynecology.
-
Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study).
Van Nuil, J. I., Umutesi, G., Shumbusho, F., Kateera, F., Dushimimana, J. de D., Muvunyi, C. M., … Gupta, N. (2020). Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study). Journal of Viral Hepatitis.
-
Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.
Shumbusho, F., Liu, A. F., Kateera, F., Kabahizi, J., Nsanzaimana, S., Serumondo, J., … Gupta, N. (2021). Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa. Journal of Viral Hepatitis.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Sep 2020
They are good to me.
SHC Patient, Aug 2020
This was important visit because of medication changes. Good discussion about why drugs were being changed.
SHC Patient, Jul 2020
Dr. Grant is an excellent doctor.
SHC Patient, Apr 2020
Dr. Grant is extremely easy to talk to, and never hurries through appointment or discussions - very thorough
SHC Patient, Apr 2020
Thank you Dr. Philip Grant.
SHC Patient, Mar 2020
Dr. Grant was on the phone as he is in the office: very professional, very personable and thorough in performing a medical investigation and patient counselling.
SHC Patient, Mar 2020
Dr. Grant is a good doctor. He always care and listens. Excellent.
SHC Patient, Mar 2020
Dr. Grant has always been a caring and attentive doctor. Very happy I am his patient.
SHC Patient, Dec 2019
Dr. Grant is very smart; he works with you to develop your own wellness approach to life; he is empathetic
SHC Patient, Oct 2019
this care provider did a good job with the device I brought and the wort froze successfully. He also prescribed pain medication I needed. He should be commended on a job well thought out.
SHC Patient, Jun 2019
Dr. Grant is one of a few truly compassionate doctors of any discipline I've ever had the pleasure of being a patient.
SHC Patient, Mar 2019
Good.
SHC Patient, Jan 2019
He seemed much more concerned about minutia, his clinic's integrity, & standard operating procedure than my unique concerns given my case is very complex & multidisciplinary.
SHC Patient, Oct 2018
Always courteous and replies/responds to my online communication through MyHealth platform.
SHC Patient, Sep 2018
Dr. Grant is awesome! A real plus to Stanford.
SHC Patient, Aug 2018
Stanford positive care is best.
SHC Patient, Feb 2018
THe dr. showed a great deal of empathy, perceptiveness and professionalism. He was very easy to speak to and he seemed to really care. I would highly recommend him to others.
SHC Patient, Jan 2018
I was seen on the same day as I called. No complaints there. Very grateful.
SHC Patient, Oct 2017
Dr. Grant is excellent in all regards.
SHC Patient, Mar 2017
I would like it if they send me or order me more punctual medications to the pharmacy so I won't miss a day since for me it is very important to take my medications.
SHC Patient, Mar 2017
Everything was good.
SHC Patient, Dec 2016
All excellent.
SHC Patient, Dec 2016
I think it takes time for Dr. Grant to get to know patients, and now we have a very good dr./patient relationship.
SHC Patient, Nov 2016
The doctor took great care to answer all my questions in detail, and was very friendly -
SHC Patient, Jun 2016
Eased some concerns and answered questions that my prior IDC doctor didn't do.
SHC Patient, Feb 2016
Love love love Dr Grant, his staff, and Stanford Medical!!
SHC Patient, Nov 2015
Dr. Grant is quite effective.
SHC Patient, Dec 2014
Dr. Grant is like a friend. I was shocked when he remembered so much about me and my personal life.
SHC Patient, Jul 2014
I drive 5 hours to see Dr. Grant. He and his staff are awesome.
SHC Patient, May 2014
The service and care was the best!
SHC Patient, Feb 2014
I really feel like I've won the lottery having such a wonderful dr. such as Dr. Grant. He is warm, attentive and helpful.
SHC Patient, Sep 2020
They are good to me.
SHC Patient, Aug 2020
This was important visit because of medication changes. Good discussion about why drugs were being changed.
SHC Patient, Jul 2020
Dr. Grant is an excellent doctor.
SHC Patient, Apr 2020
Dr. Grant is extremely easy to talk to, and never hurries through appointment or discussions - very thorough
SHC Patient, Apr 2020
Thank you Dr. Philip Grant.
SHC Patient, Mar 2020
Dr. Grant was on the phone as he is in the office: very professional, very personable and thorough in performing a medical investigation and patient counselling.
SHC Patient, Mar 2020
Dr. Grant is a good doctor. He always care and listens. Excellent.
SHC Patient, Mar 2020
Dr. Grant has always been a caring and attentive doctor. Very happy I am his patient.
SHC Patient, Dec 2019
Dr. Grant is very smart; he works with you to develop your own wellness approach to life; he is empathetic
SHC Patient, Oct 2019
this care provider did a good job with the device I brought and the wort froze successfully. He also prescribed pain medication I needed. He should be commended on a job well thought out.
SHC Patient, Jun 2019
Dr. Grant is one of a few truly compassionate doctors of any discipline I've ever had the pleasure of being a patient.
SHC Patient, Mar 2019
Good.
View All 31 Patient Comments »